| Mrs Rita Y Colon, | |
|
Urb Colinas De Hatillo, Calle Colinas B-12, Hatillo, PR 00659 | |
| (787) 397-9825 | |
| Not Available |
| Full Name | Mrs Rita Y Colon |
|---|---|
| Gender | Female |
| Speciality | Counselor - Professional |
| Location | Urb Colinas De Hatillo, Hatillo, Puerto Rico |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1366688558 | NPI | - | NPPES |
| 2404 | Other | PR | STATE LICENCE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 101YP2500X | Counselor - Professional | 2404 (Puerto Rico) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Rita Y Colon, Po Box 1490, Hatillo, PR 00659-1490 Ph: (787) 397-9825 | Mrs Rita Y Colon, Urb Colinas De Hatillo, Calle Colinas B-12, Hatillo, PR 00659 Ph: (787) 397-9825 |
News Archive
Janssen Biotech, Inc., one of the Janssen pharmaceutical companies of Johnson & Johnson announced today an exclusive, worldwide license agreement with Alligator Bioscience AB for ADC-1013, an immuno-oncology agent currently in Phase 1 clinical studies.
If you're one of the roughly 48,000 Dallas-Fort Worth area residents struggling with pain from psoriatic arthritis (PsA)—an inflammatory autoimmune disease that causes pain, swelling and stiffness of the joints and tendons—learn to control your condition with Be Joint Smart, a free psoriatic arthritis program presented by the National Psoriasis Foundation, at the Dallas Marriott Las Colinas on December 6.
A hormonal condition known as subclinical hypothyroidism is associated with an increased risk of congestive heart failure among older adults, but not with other cardiovascular events and death, according to a study in the November 28 issue of Archives of Internal Medicine.
Cold atmospheric plasma technology, currently the only way to remove microscopic cancer tumors remaining from surgery, has been approved by the U.S. Food and Drug Administration for first-ever use in a clinical trial.
Melior Discovery, Inc. announced today the United States Patent and Trademark Office (USTPO) has awarded a Notice of Allowance for a broad patent application covering the Company's use of MLR-1023 for, among other things, the treatment of type II diabetes and obesity. The patent will cover use of MLR-1023 for the treatment of type II diabetes, obesity and metabolic syndrome, including its use in combination with other compounds and as a component in other drugs.
› Verified 1 days ago
Miss Carmen Galiano, CPL Counselor Medicare: Not Enrolled in Medicare Practice Location: Hc 1 Box 12027, Hatillo, PR 00659 Phone: 787-473-7488 | |
Patricia Nelson, Counselor Medicare: Not Enrolled in Medicare Practice Location: Cedro Street 181, Estancias De La Ceiba, Hatillo, PR 00659 Phone: 787-378-7492 |